ReviewDrug Development

Engineering biopharmaceutical formulations to improve diabetes management

See allHide authors and affiliations

Science Translational Medicine  27 Jan 2021:
Vol. 13, Issue 578, eabd6726
DOI: 10.1126/scitranslmed.abd6726

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Insulin was first isolated almost a century ago, yet commercial formulations of insulin and its analogs for hormone replacement therapy still fall short of appropriately mimicking endogenous glycemic control. Moreover, the controlled delivery of complementary hormones (such as amylin or glucagon) is complicated by instability of the pharmacologic agents and complexity of maintaining multiple infusions. In this review, we highlight the advantages and limitations of recent advances in drug formulation that improve protein stability and pharmacokinetics, prolong drug delivery, or enable alternative dosage forms for the management of diabetes. With controlled delivery, these formulations could improve closed-loop glycemic control.

View Full Text

Stay Connected to Science Translational Medicine